Intraneuronal aggregates of neurofibrillary tangles (NFTs), together with beta-amyloid plaques and astrogliosis, are histological markers of Alzheimer's disease (AD). The underlying mechanism of sporadic AD remains poorly understood, but abnormal hyperphosphorylation of tau protein is suggested to have a role in NFTs genesis, which leads to neuronal dysfunction and death. Okadaic acid (OKA), a strong inhibitor of protein phosphatase 2A, has been used to induce dementia similar to AD in rats. We herein investigated the effect of intracerebroventricular (ICV) infusion of OKA (100 and 200 ng) on hippocampal tau phosphorylation at Ser396, which is considered an important fibrillogenic tau protein site, and on glucose uptake, which is reduced early in AD. ICV infusion of OKA (at 200 ng) induced a spatial cognitive deficit, hippocampal astrogliosis (based on GFAP increment) and increase in tau phosphorylation at site 396 in this model. Moreover, we observed a decreased glucose uptake in the hippocampal slices of OKA-treated rats. In vitro exposure of hippocampal slices to OKA altered tau phosphorylation at site 396, without any associated change in glucose uptake activity. Taken together, these findings further our understanding of OKA neurotoxicity, in vivo and vitro, particularly with regard to the role of tau phosphorylation, and reinforce the importance of the OKA dementia model for studying the neurochemical alterations that may occur in AD, such as NFTs and glucose hypometabolism.
Introduction
Alzheimer's disease (AD), the most common form of dementia, is an age-related neurodegenerative disorder, characterized clinically by loss of memory and personality changes and histopathologically by the presence of the extraneuronal accumulation of beta-amyloid peptides in plaques, intraneuronal aggregates of neurofibrillary tangles (NFTs) and astrogliosis in neocortical and hippocampal tissues (Feany and Dickson, 1996; Raskin et al., 2015; Stephan et al., 2001) . The underlying mechanism of sporadic AD remains poorly understood, but it has been shown that abnormal hyperphosphorylation of tau leads to aggregation, formation of NFTs, microtubule disruption, neuronal dysfunction and death (Brandt et al., 2005; Li et al., 2007) .
It is well established that brain glucose uptake/metabolism is impaired in AD (Cunnane et al., 2011) and it has been proposed that this impairment is linked to abnormal hyperphosphorylation of tau (Gong et al., 2006) . In this scenario, astrocytes are key elements, particularly because changes in glucose uptake and/or glutamate uptake affect neuronal function and survival [see Steele and Robinson, 2012 for a review] .
Several transgenic and non-transgenic animal models have been proposed for studying the genesis of AD, where each model allows us to investigate specific aspects of this disease, its different phases and even possible therapeutic strategies (Puzzo et al., 2015) . To specifically investigate NFTs, several transgenic models have been developed [see (Brandt et al., 2005) for a review], while non-transgenic models include the intracerebroventricular (ICV) or intrahippocampal infusion of okadaic acid (OKA) (Costa et al., 2012; Kamat et al., 2010) .
OKA is a selective inhibitor of the serine/threonine phosphatases 2A (predominantly) and 1 (Arias et al., 1998) , which mediate the phosphorylation of the tau protein and, therefore, neuronal cell death in vitro (Cagnoli et al., 1996) and in vivo (He et al., 2001) . Importantly, it has been shown that the activity of protein phosphatase 2A (PP2A) is decreased in the brains of AD patients (Zhou et al., 2008) . Based on this and other evidence, PP2A has been suggested to be a putative molecular target in the treatment of Alzheimer's disease (Voronkov et al., 2011) .
Using a model of intrahippocampal OKA-injection in rats we observed behavioral and neuroglial alterations (Costa et al., 2012) in these animals. Our findings indicated significant hippocampal changes, including gliosis (based on the increased GFAP content) with a reduction in glutamine synthetase (GS), an enzyme responsible for the recycling of glutamate for glutamatergic transmission. Moreover, we found an activation of p38 MAPK in this model, an enzyme putatively involved in the phosphorylation of tau and elevated in AD (Munoz and Ammit, 2010; Pei et al., 2003) .
In vitro phosphorylation of tau occurs at multiple sites and appears to be required to convert it into the altered protein [see (Stoothoff and Johnson, 2005) , for a review]. Phosphorylation at Ser262 and Thr231/Ser235 seems to regulate tau microtubule interactions. Under pathological conditions, tau hyperphosphorylation at the critical microtubule regulatory sites leads to increased levels of free tau, which result in further tau phosphorylation at fibrillogenic sites (e.g. Ser396/404).
In this study, we employed a model of ICV-OKA administration to investigate tau phosphorylation (at Ser396) and other biochemical changes commonly associated with cognitive impairment, including glucose uptake, gliosis markers (GFAP and S100B) and parameters related to glutamate metabolism (glutamate uptake, GS and glutathione (GSH) content). Moreover, we investigated whether OKA has a direct effect on tau phosphorylation and other biochemical parameters in acute hippocampal slices.
Material and methods

Animals
Forty-seven adult male Wistar rats (300-380 g, 100 days old) were obtained from our breeding colony (Department of Biochemistry, Federal University of Rio Grande do Sul, Brazil) and were maintained under controlled light and environmental conditions (12 h light/12 h dark cycle at a constant temperature of 22 ± 1 • C) with free access to food and water. All animal experiments were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (NIH Publications no. 80-23) and followed the regulations of the local animal house authorities (UFRGS, no. 20356).
Surgical procedures
To analyze the in vivo effect of okadaic acid (OKA; from Calbiochem), thirty-eight animals were divided into three groups: sham/vehicle (n = 12), 100 ng OKA (n = 13) and 200 ng OKA (n = 13) groups. Cognitive evaluations were performed between 14 and 20 days after OKA administration, and on day 21 after OKA administration, rats were anesthetized for cerebrospinal fluid (CSF) puncture. Then animals were euthanized by decapitation and hippocampal samples were obtained for biochemical analyses.
OKA was dissolved in dimethyl sulfoxide (DMSO) at a concentration of 0.29 mM and diluted to an appropriate concentration in phosphate buffer saline (D-PBS, 16% of DMSO). Briefly, on the day of the surgery, animals were anesthetized with ketamine/xylazine (80 and 10 mg/kg, respectively, intraperitoneally) and placed in a stereotaxic apparatus. A midline sagittal incision was made in the scalp. Burr holes were drilled in the skull on both sides over the lateral ventricules. The lateral ventricles were accessed using the following coordinates (Tramontina et al., 2011) : 0.9 mm posterior to bregma; 1.5 mm lateral to sagittal suture; 3.6 mm beneath the surface of the brain. Rats received a bilateral infusion, in a total volume of 10 L, of OKA (10 ng/L or 20 ng/L) or vehicle (D-PBS) using a microsyringe (Hamilton, USA). After the surgical procedure, rats were placed on a heating pad to maintain body temperature at 37.5 ± 0.5 • C and were kept there until recovery from anesthesia. No mortality was observed in either of the groups.
Cognitive and motor evaluation
Fourteen days after surgery, rats were submitted to training in the Morris water maze (Morris, 1984) . The apparatus consisted of a circular pool (180 cm diameter, 60 cm high) filled with water (depth 30 cm; 24 ± 1 • C), placed in a room with consistently located spatial cues. An escape platform (10 cm diameter) was placed in the middle of one of the quadrants, 1.5 cm below the water surface, equidistant from the sidewall and the middle of the pool. The platform provided the only escape from the water and was located in the same quadrant every trial. Four different starting positions were equally spaced around the perimeter of the pool. On each training day, all four start positions were used once in a random sequence, i.e., four training trials per day. A trial began by placing the animal in the water facing the wall of the pool at one of the starting points. If the animal failed to escape within 60 s it was gently conducted to the platform by the experimenter. The rat was allowed to stay there for 20 s. The inter-trial interval was 10 min. After each trial, the rats were dried, and returned to their cages at the end of the session. Animals were trained for 6 days. 24 h after the last training session, the rats were submitted to a test session. Before this session, the submerged platform was removed. The retention test consisted of placing the animals in the water for 1 min. On the day of the test, animals were placed in the opposite quadrant to where the time to find the platform and speed were measured. The data were analyzed with ANY-maze software version 4.99.
Collection of cerebrospinal fluid and hippocampal slices
Animals were anesthetized as previously described and then positioned in a stereotaxic holder and cerebrospinal fluid (CSF) was obtained by cisterna magna puncture. The puncture was performed using an insulin 0.5 mL syringe and 31 G needle (0.25 mm diameter, 6 mm length). CSF samples were frozen (−80 • C) until S100B measurement (Guerra et al., 2011; Rodrigues et al., 2009 ). The animals were killed by decapitation, the brains were removed and placed in cold sodium phosphate buffer with the following composition (in mM): 51.33 NaCl, 19.13 NaH 2 PO 4 ·H 2 O, 81.01 Na 2 HPO 4 , pH 7.4. The left hippocampi were dissected and quickly frozen in liquid nitrogen and stored in −80 • C until western blotting analysis. The right hippocampi were chopped obtained transverse slices of 0.3 mm using a McIlwain Tissue Chopper (Nardin et al., 2009) . Hippocampal slices were transferred immediately to 24-well culture plates for measuring glutamate and glucose uptake or frozen (−80 • C) for other biochemical analysis (GFAP, GSH content and glutamine synthetase activity) as subsequently described.
Western blotting analysis for tau content and phosphorylation
Hippocampal slices were homogenized in sample buffer (62.5 mM Tris-HCl, pH 6.8, 10% (v/v) glycerol, 2% (w/v) SDS, 5% (w/v) ␤-mercaptoethanol and 0.002% bromphenol blue) and proteins were separated by SDS-PAGE on 10% (w/v) acrylamide gels and electrotransferred onto nitrocellulose membranes. Membranes were incubated in TBS-T (20 mmol/L Tris-HCl, pH 7.5, 137 mmol/L NaCl, 0.05% (v/v) Tween-20) containing 5% (w/v) milk for 1 h at room temperature. Subsequently, the membranes were incubated overnight with the appropriate primary antibodies: anti-phosphoTau (Ser396), clone PHF13 (dilution 1:1000) (Merck Millipore); anti-Tau, clone Tau 7 (dilution 1:1000) (Merck Millipore); or anti-␤-actin (dilution 1:2000) (Sigma Aldrich). Membranes were then rinsed with TBS-T, and exposed to horseradish peroxidase-linked anti-IgG antibodies for 2 h at room temperature. Chemiluminescent bands were detected using a chemiluminescence ECL kit (GE Healthcare) and captured in an ImageQuant LAS400 (GE). Densitometry analyses were performed using Image-J software. The results were expressed as percentages of the control and the levels of phosphorylation were determined as a ratio of phospho-Tau ser396/Total Tau.
GFAP content
Enzyme-linked immunosorbent assay for GFAP was carried out, as previously described (Tramontina et al., 2007) , by coating the microtiter plate with 100 L diluted samples or standard human GFAP (Calbiochem) ranging from 0.1 to 5 ng for 24 h at 4 • C. Incubation with a rabbit polyclonal anti-GFAP (Dako) for 1 h was followed by incubation with a secondary antibody conjugated with peroxidase for 1 h, at room temperature (GE). A colorimetric reaction with o-phenylenediamine (Sigma) was measured at 492 nm. Data were calculated as ng/g total protein.
2.7. S100B measurement S100B was measured by an enzyme-linked immunosorbent assay, as previously described (Leite et al., 2008) . Briefly, 50 L of sample plus 50 L of Tris buffer were incubated for 2 h on a microtiter plate previously coated overnight with monoclonal anti-S100B (SH-B1) antibody (Sigma). Polyclonal anti-S100 antibody (Dako) and peroxidase-conjugated anti-rabbit antibody (GE) were incubated at the same time for 30 min at 37 • C. The microtiter plate was rinsed three times with a wash solution between each step of the technique. A colorimetric reaction with o-phenylenediamine (Sigma) was measured at 492 nm. The standard S100B curve ranged from 0.002 to 1 ng/mL. Data were calculated as ng/mL.
Glutamate uptake assay
Glutamate uptake was performed as previously described (Thomazi et al., 2004) . Slices were incubated at 37 • C in Hank's Balanced Salt Solution (HBSS) containing (in mM): 137 NaCl, 5.36 KCl, 1.26CaCl 2 , 0.41 MgSO 4 , 0.49 MgCl 2 , 0.63 Na 2 HPO 4 ·7H 2 O, 0.44 KH 2 PO 4 , 4.17 NaHCO 3 and 5.6 glucose, pH 7.2. The assay was started by the addition of 0.1 M l-glutamate and 0.33 Ci/mL L-[2,3-3 H] glutamate (Amersham International). The incubation was stopped after 5 min by removing the medium and rinsing the slices twice with ice-cold HBSS. The slices were then lysed in a 0.5 M NaOH solution. Sodium-independent uptake was determined using N-methyl-d-glucamine (Sigma) instead of NaCl. Sodiumdependent glutamate uptake was obtained by subtracting the non-specific uptake from the total uptake to obtain the specific uptake. Radioactivity was measured in a scintillation counter. Results were calculated as nmol/mg protein/min.
Glutamine synthetase(GS) activity
The enzymatic activity of GS was determined using procedures described previously (Minet et al., 1997) , with modifications. Briefly, slices were homogenized in 50 mM imidazole.
Homogenates were incubated with (mM): 50 imidazole, 50 hydroxylamine, 100 L-glutamine, 25 sodium arsenate dibasic heptahydrate, 0.2 ADP, 2 manganese chloride, pH 6.2 for 15 min at 37 • C. The reactions were terminated by the addition of 0.2 mL of 0.37 M FeCl 3 , 200 mM trichloroacetic acid, and 67 mM HCl. After centrifugation, the absorbance of the supernatant was measured at 530 nm and compared to the absorbance generated by standard quantities of ␥-glutamylhydroxamate acid treated with ferric chloride reagent. GS activity was expressed as mol/mg protein/h.
Glucose uptake assay
Glucose uptake was measured as previously described (Pellerin and Magistretti, 1994) , with modifications (Hansen et al., 2016) . Hippocampal slices were incubated at 35 • C in HBSS (described above). The assay was initiated by the addition of 0.1 Ci/well Deoxy-d-glucose, 2-[ 3 H(G)]. The incubation was stopped after 30 min by removing the medium and rinsing the slices twice with ice-cold HBSS. The slices were then lysed in a solution containing 0.5 M NaOH. Glucose uptake was calculated by subtracting the non-specific uptake, obtained by the glucose transporter inhibitor, cytochalasin B (10 M), from the total uptake in order to obtain the specific uptake. Radioactivity was measured using a scintillation counter. Results were calculated as nmol/mg protein/min.
Glutathione (GSH) content assay
Intracellular GSH levels (nmol/mg protein) were measured as previously described (Browne and Armstrong, 1998) . This assay detects only the reduced glutathione content. Slices were diluted in ten volumes of 100 mM sodium phosphate buffer, pH 8.0, containing 5 mM EDTA and protein was precipitated with 1.7% meta-phosphoric acid. Supernatant was assayed with ophthaldialdehyde (1 mg/mL methanol) at room temperature for 15 min. Fluorescence was measured using excitation and emission wavelengths of 350 and 420 nm, respectively. A calibration curve was employed using standard GSH solutions (0-500 M). Results were calculated as nmol/mg protein.
Protein determination
Protein content was measured by Lowry's method using bovine serum albumin as standard (Peterson, 1977) .
In vitro effect of OKA in hippocampal slices
To analyze the direct and acute effect of the OKA in hippocampi slices, other nine (n = 9) adult male rats were used. Animals were killed by decapitation, the brains were removed and placed in cold saline medium with the following composition (in mM): 120 NaCl; 2 KCl; 1 CaCl 2 ; 1 MgSO 4 ; 25 HEPES; 1 KH 2 PO 4 and 10 glucose, adjusted to pH 7.4. The hippocampi were dissected and transverse slices of 0.3 mm were obtained using a McIlwain Tissue Chopper. Slices were then transferred into 24-well culture plates, each well containing 0.3 mL of appropriate media for glutamate uptake or glucose uptake assay (as described in Sections 2.8 and 2.10, respectively) or protein phosphorylation assay, containing OKA 0.3 ng/L or OKA 0.6 ng/L or vehicle (DMSO at final concentration of 0.5%). For protein phosphorylation assay, slices were incubated in saline medium for 60 min, at 30 • C (Ziegler et al., 2002) and tau phosphorylation content was determined by western blotting (as described in Section 2.5). Amounts of OKA for in vitro experiments were chosen based on amount injected in vivo (100 and 200 ng in a putative CSF volume of 300 L in rats) (Consiglio and Lucion, 2000) . Integrity Values are mean ± standard error of 7-9 rats in each group. *Significant differences from the sham group (One-way ANOVA followed by Tukey's test, p < 0.05).
and viability of the slice preparations were evaluated by LDH and MTT assays (Nardin et al., 2009 ) (data not shown).
Statistical analysis
Data are reported as means ± standard error and analyzed statistically by one-way analysis of variance (ANOVA), followed by Tukey's test. Differences were considered to be significant when p < 0.05. All analyses were performed using the SPSS software package 20.0.
Results
Cognitive and motor performance
The Morris water maze was used to evaluate cognitive impairment with ICV administration in the groups: Sham, 100 ng OKA and 200 ng OKA. In the training sessions (started 2 weeks after OKA administration), a significant decline was observed in the average time to find the platform (escape latency) (data not shown). In the trial session, the time to find the platform was significantly higher in the group that received 200 ng OKA (Fig. 1A , one way ANOVA, F(2, 20) = 4.554, p = 0.02). The use of ANY-Maze to analyze the locomotor activity (immobility time, travelled distance and speed) showed that OKA-treated rats exhibit similar mobility when compared with the sham group. Speed data is presented in Fig. 1B (one way ANOVA, F(2, 18) = 0.688, p = 0.5).
Tau content and phosphorylation
A significant increase in the phospho-tau immunocontent (oneway ANOVA, F(2, 14) = 7.379, p = 0.006) of the hippocampus was (Sham) or OKA (at 100 or 200 ng) was ICV injected. Neurochemical analysis was performed 3 weeks afterwards. Hippocampal slices were analyzed by SDS-PAGE and western blotting. In (A) phosphorylated tau at Ser396; In (B) total tau content; and in (C) phosphorylated tau/Total tau ratio. Representative images of blots of phosphorylated tau, tau and beta actin were inserted in the top of panels. Values are mean ± standard error of 5-6 rats in each group. *Significantly different from the sham group. #Significantly differences from the OKA 100 group (One-way ANOVA followed by Tukey's test, p < 0.05).
observed in treated rats with ICV-OKA at 200 ng, but not at 100 ng ( Fig. 2A) . However, we did not observe differences in the amount of total tau among the groups (Fig. 2B, F(2, 14) = 1.158, p = 0.34). The phospho-tau/tau ratio demonstrates a clear increase in tau phosphorylation following 200 ng OKA administration (Fig. 2C, F(2,  14) = 5.384, p = 0.01).
Hippocampal GFAP and CSF S100B
The GFAP content was increased in the rat hippocampus at 3 weeks after ICV-OKA at 200 ng (Fig. 3A, F(2, 26) = 3.58, p = 0.04). No change was observed in the hippocampal S100B content after Fig. 3 . Hippocampal GFAP and cerebrospinal fluid S100B of rats submitted to OKAintracerebroventricular infusion. Wistar rats were anesthetized and vehicle (Sham) or OKA (at 100 or 200 ng) was ICV injected. Neurochemical analysis was performed 3 weeks afterwards. In (A) hippocampal slices were homogenized and GFAP content was measured by ELISA. In (B) cerebrospinal fluid (CSF) was collected by cisterna magna puncture and the S100B was measures by ELISA. Values are mean ± standard error of 7-11 rats in each group. *Significantly different from the sham group. (Oneway ANOVA followed by Tukey's test, p < 0.05).
this treatment (data not shown); however a decrease in CSF S100B was observed (Fig. 3B, F(2, 22) = 4.889, p = 0.018) in both groups of OKA-treated rats.
Glutamate uptake and GS activity
Glutamate uptake (predominantly) and glutamate synthetase (exclusively) are markers of astroglial activity. After ICV-OKA, we observed an apparent (not significantly) decrease in glutamate uptake (Fig. 4A, F(2, 11) = 0.6200, p = 0.5557) and in glutamate synthetase (Fig. 4B, F(2, 35) = 1.881, p = 0.1675), at both concentrations of OKA.
Glucose uptake and GSH content
Astrocytes synthesize GSH, and also recycle it using NADPH from the pentose pathway. Part of the GSH is exported and its product (cysteinylglycinepeptide) is taken up and used by neurons to synthesize its own GSH. Hippocampal glucose uptake was reduced in rats treated with ICV-OKA at 200 ng (Fig. 5A, F(2, 33) = 7.244 and p = 0.0025), suggesting a decrease in glucose uptake. However, no changes were observed in the hippocampal content of GSH (Fig. 5B , F(2, 21) = 0.1021 and p = 0.9034).
In vitro effect of OKA on tau phosphorylation
Acute hippocampal slices were incubated for 1 h with OKA at concentrations of 0.3 and 0.6 ng/L, in order to investigate a direct effect on tau phosphorylation at Ser396. A significant increase in phosphorylated tau (Fig. 6A, F(2, 12) = 4.413, p = 0.0366) was observed in hippocampal slices incubated with 0.6 ng/L OKA. As expected, we did not observe changes in the amount of total tau Values are mean ± standard error of 4-5 rats in each group in glutamate uptake assays and 10-13 in each group in GS assays. No differences were found between groups. One-way ANOVA followed by Tukey's test, p < 0.05. Fig. 5 . Glucose uptake and glutathione (GSH) content in the hippocampus of rats submitted to OKA-intracerebroventricular infusion. Wistar rats were anesthetized and vehicle (Sham) or OKA (at 100 or 200 ng) was ICV injected. Neurochemical analysis was performed 3 weeks afterwards. In (A) hippocampal slices of 0.3 mm thickness were incubated with 3 H-glucose for measurement of glucose uptake. In (B) GSH was measured in homogenized hippocampal slices. Values are mean ± standard error of 8-10 rats in each group. *Significantly different from the sham group (One-way ANOVA followed by Tukey's test, p < 0.05). . Content and phosphorylation of tau protein in hippocampal slices incubated with OKA. Hippocampal slices of male Wistar rats were incubated with OKA (0.3 or 0.6 ng/mL) for 1 h and analyzed by SDS-PAGE and western blotting In (A) phosphorylated tau at Ser 396; in (B) total tau content; and in (C) phosphorylated tau/Total tau ratio. Representative images of blots of phosphorylated tau, tau and beta actin were inserted in the top of panels. Values are mean ± standard error of 4-5 experiments in each group. *Significantly different from the sham group (One-way ANOVA followed by Tukey's test, p < 0.05).
( Fig. 6B, F(2, 12) = 1.750, p = 0.2154). However, significant increases in the phospho-tau/tau ratio were induced by 0.3 and 0.6 ng/L OKA (Fig. 6C, F(2, 12) = 0.6078, p = 0.0167). The integrity and viability of these slices were evaluated and confirmed by LDH and MTT assays, respectively (data not shown).
3.7.
In vitro effect of OKA on glucose and glutamate uptake OKA incubation did not directly affect glutamate (Fig. 7A,  F(2, 14) = 0.810, p = 0.0998) and glucose (Fig. 7B, F(2, 23) = 0.1510, p = 0.8607) uptake in hippocampal slices. However, a tendency Hippocampal slices of male Wistar rats were incubated with OKA (0.3 or 0.6 ng/mL) for 1 h. Slices were then incubated with media containing 3 H-glutamate or 3 HDeoxy-d-glucose for measurement of glutamate uptake (in A) or glucose uptake (in B), respectively. Values are mean ± standard error of 5-8 experiments in each group. No differences were found. One-way ANOVA followed by Tukey's test, p < 0.05.
(p < 0.10) towards a reduction in glutamate uptake occurred in slices incubated with OKA at 0.6 ng/L.
Discussion
Epidemiological studies reveal the growing importance of dementias in public heath, particularly AD, with consequently high social and economic impacts (Chatterjee et al., 2016; Prince et al., 2013) . Causes of this neurodegenerative disease remain unknown. Among the histopathological markers of AD are amyloid plaques (due to the deposition of beta amyloid peptide) and aggregates of NFTs (due to hyperphosphorylation of the tau protein) (Goedert and Spillantini, 2006; Silvestrelli et al., 2006) . The mechanism(s) leading to hyperphosphorylation of tau or even beta amyloid deposition are unclear, but brain glucose hypometabolism appears to precede these alterations in AD (Mosconi et al., 2009; Weinstock and Shoham, 2004) . In fact, models based on reduced glucose uptake/metabolism have been widely used to study AD and to propose therapeutic strategies (Agrawal et al., 2011; Biasibetti et al., 2013) .
In order to specifically investigate NFTs formation, ICV and intrahippocampal infusions of OKA have been used (Costa et al., 2012; Kamat et al., 2010) . OKA, a selective inhibitor of serine/threonine phosphatases 1 and 2B, causes phosphorylation of the tau protein and neuron death (Cagnoli et al., 1996; He et al., 2001) . Tau phosphorylation occurs at multiple sites [see (Stoothoff and Johnson, 2005) , for a review]. Phosphorylation at Ser262 and Thr231/Ser235 regulate tau microtubule interactions, but the hyperphosphorylation of these sites, under pathological conditions, favors tau dissociation from microtubules and its subsequent phosphorylation at sites Ser396/404, considered as fibrillogenic sites.
Protein phosphatases 2A and 2B dephosphorylate tau at Ser396, but PP2A also dephosphorylate tau at additional sites. In fact, in the rat brain, PP2A has major activity at tau phosphorylated sites, and targets several protein kinases (Lee et al., 2001 ).
In the OKA-induced model dementia, hyperphosphorylation at Ser262 has been described (Kamat et al., 2013) . Herein, we investigated tau phosphorylation, induced by OKA, at site Ser396 in hippocampal slices from rats treated with ICV-OKA and acute hippocampal slices of untreated rats. In both conditions we observed an increase in tau phosphorylation without significant changes in the tau content. To our knowledge, this is the first time that the increase in phosphorylation has been shown at this site in the OKAinduced model of dementia. These data, together with evidence of cognitive impairment in these animals, support the use of the OKA model as a useful tool for the study of AD genesis. Moreover, to date, no direct data regarding hippocampal glucose metabolism have been reported in the OKA-induced model of dementia.
Herein, we observed a decrease in glucose uptake in ICV-OKA treated rats, a finding that is also of importance to validate this model for AD. As mentioned, brain hypometabolism of glucose appears to precede cognitive impairment and explain, in part, the elevated risk for AD reported in diabetic patients (Agrawal et al., 2011; Chen and Zhong, 2013; Weinstock and Shoham, 2004) . However, OKA exposure was not able to induce changes in glucose uptake in acute hippocampal slices, as observed in the in vivo model. Many variables could be involved in this discrepancy. The simplest idea is that OKA, in our conditions, does not directly affect hippocampal glucose uptake and the in vivo effect involves long-term alterations in the expression of transporter(s) or in the regulation of this/these transporter(s). In fact, the effects of OKA are suggested to depend on cell type, time exposure and concentration (Atkinson et al., 2009) . OKA (at M levels), in the skeletal muscle (Tanti et al., 1991) , hepatocytes (Quentmeier et al., 1993) and adipocytes (Li et al., 1996) , is able to induce glucose metabolism. On the other hand, OKA at 10 nM was found to protect cortical neurons from oxygen-glucose deprivation (Atkinson et al., 2009 ), but it could be lethal at concentrations of 40 nM or more (Yi et al., 2005) . The mechanisms behind these effects of OKA on glucose metabolism are not fully understood, but involve changes in enzymatic activities (due to the protein phosphorylation status) and protein expression (Valdiglesias et al., 2012) .
Using ICV-OKA we observed two signals of astroglial reactivity; an increase in GFAP, a classical marker of gliosis and a decrease in CSF S100B, an alteration that is observed in other models of dementia, such as STZ (Biasibetti et al., 2013; Rodrigues et al., 2009; Tramontina et al., 2011) , chronic cerebral hypoperfusion (Vicente et al., 2009 ) and intrahippocampal OKA injection (Costa et al., 2012) . Considering the neurotrophic activity of S100B, its extracellular decrease in these models may reflect the loss of glial capacity to secrete and respond to injury. In fact, a decrease in astroglial activity (including glucose metabolism) has been proposed to represent a preceding event in cases of dementias, particularly AD (Mosconi et al., 2009; Raskin et al., 2015) . We may speculate that a decrease in CSF S100B may be a useful and complementary marker for cognitive impairment and dementia.
The most abundant synaptic transmission is glutamatergic type transmission, which is intimately dependent on astroglial activity. Alterations in this type of synapse are involved in all brain diseases, and changes in cognitive behavior in patients and animals models have been associated with alterations in hippocampal glutamatergic communication. In fact, the OKA-induced model of dementia has been shown to cause significant changes in glutamatergic neurotransmission. Intrahippocampal administration of OKA, for example, has been shown to cause a glutamatergic dysfunction that could be prevented by memantine (Zimmer et al., 2012) . Elevated levels of CSF glutamate were observed in this model. More recently, the increased expression of two subunits of the NMDA receptors (NR1 and NR2B) has been found to consolidate glutamatergic dysfunction in the ICV-OKA model of dementia (Kamat et al., 2014) . Our data reinforce the hypothesis that astrocytes play a role in glutamatergic communication. Using intrahippocampal OKA, we found a decrease in hippocampal GS (Costa et al., 2012) , which was not observed following the ICV-OKA administration described herein. However, if we look at the glutamate uptake/GFAP ratio, where there is a tendency towards a decrease in glutamate uptake in contrast to a clear increase in GFAP (at 200 ng ICV-OKA), it is possible conceive a reduced capacity of glutamate uptake in glial cells, possibly contributing to the excitotoxicity mediated by NMDA receptors.
A limitation of this work should be highlighted. Oxidative stress was not exhaustively investigated in the current study, as only the reduced glutathione content was determined (measured by its reaction with o-phthaldialdehyde), and this parameter was not affected under the conditions used. This contrasts with previous results using ICV-OKA administration that demonstrated a decrease in GSH content, as determined by its reaction with 5,5 -dithiobis 2-nitrobenzoic acid (Kamat et al., 2010; Kamat et al., 2014) . Moreover, regardless of methodological differences, we also observed a decrease in GSH after intrahippocampal OKA-administration (Costa et al., 2012) .
Conclusions
In summary, ICV infusion of OKA (200 ng) induced a spatial cognitive deficit, a behavioral task dependent on hippocampus integrity, and also induced gliosis in this brain region (based on GFAP increment), similarly to that obtained with a direct hippocampal OKA-lesion (Costa et al., 2012) . The decrease in CSF S100B reinforces the idea of glial impairment. Importantly, we observed, for the first time to our knowledge, tau phosphorylation at site 396 in this model, which was directly involved in the genesis of NFTs, an important histological marker for AD characterization. Moreover, we observed a decrease in glucose uptake in the hippocampal slices of OKA treated rats, which is, putatively, a metabolic alteration that precedes and accompanies AD. Additionally, we found a direct effect of OKA incubation on tau phosphorylation at site 396 in hippocampal slices, without any associated change in glucose uptake activity. These findings contribute to our understanding of OKA neurotoxicity, in vivo and vitro, particularly with regard to tau phosphorylation. Our data also reinforce the importance of the OKA model of dementia for the generation of neurochemical alterations found in AD, such as NFTs and hypometabolism of glucose.
